TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tenaya Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.38−0.00 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $82.16M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
24.0%
54M of 224M shares
Institutional holders
101
18 new, 19 sold out
Net institutional buying
-3M
In Q2 2026
Insider trades, 12 months
0 buys · 35 sales
Net sold $5.97M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Martin D. Hoe | 8,727,314 | 9.96% | 13G (passive) | Mar 31, 2025 |
| Tim Kutzkey | 54,313,559 | 25.40% | 13D (active) amendment | Feb 10, 2026 |
| Peter Svennilson | 49,313,559 | 23.10% | 13D (active) amendment | Feb 25, 2026 |
| TCG Opportunity III GP, LLC | 49,313,559 | 23.10% | 13D (active) amendment | Dec 15, 2025 |
| The Column Group Opportunity III GP, LP | 49,313,559 | 30.30% | 13D (active) amendment | May 7, 2025 |
| Millennium Management LLC | 11,581,565 | 5.20% | 13G (passive) | Aug 17, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TNYA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 7,101,263 | 3.17% | $5.25M | −1,381,025 | 0.00% |
| Millennium Management LLC | 6,429,648 | 2.87% | $4.75M | +972,982 | 0.00% |
| Citadel Advisors LLC | 4,566,774 | 2.04% | $3.38M | +366,774 | 0.00% |
| Renaissance Technologies LLC | 4,281,100 | 1.91% | $3.16M | +567,339 | 0.00% |
| BlackRock, Inc. | 4,008,719 | 1.79% | $2.96M | +304,764 | 0.00% |
| Empery Asset Management, LP | 3,863,115 | 1.72% | $2.86M | −423,818 | 3.30% |
| Marshall Wace, Llp | 3,503,178 | 1.56% | $2.59M | +797,788 | 0.00% |
| Gsa Capital Partners Llp | 2,669,033 | 1.19% | $1.97K | +1,596,122 | 0.12% |
| Burkehill Global Management, LP | 2,000,000 | 0.89% | $1.48M | – | 0.05% |
| Geode Capital Management, LLC | 1,834,674 | 0.82% | $1.36M | +274,735 | 0.00% |
| ADAR1 Capital Management, LLC | 1,555,500 | 0.69% | $1.15M | +47,700 | 0.05% |
| Raiffeisen Bank International AG | 1,200,000 | 0.54% | $881.88K | +200,000 | 0.01% |
| Euclidean Capital LLC | 1,015,705 | 0.45% | $750.71K | – | 0.17% |
| Vanguard Fiduciary Trust Co | 987,505 | 0.44% | $729.77K | −28,197 | 0.00% |
| Mirador Capital Partners LP | 905,097 | 0.40% | $668.96K | +18,180 | 0.08% |
| State Street Corp | 708,721 | 0.32% | $523.82K | – | 0.00% |
| Squarepoint Ops LLC | 659,247 | 0.29% | $487.25K | +310,979 | 0.00% |
| StepStone Group LP | 462,163 | 0.21% | $341.54K | – | 0.02% |
| UBS Group AG | 456,555 | 0.20% | $337.39K | −208,625 | 0.00% |
| Jane Street Group, LLC | 450,435 | 0.20% | $332.92K | −729,646 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 101 | 54M | 24.0% | 18 / 32 | 17 / 19 | 7M | 10M |
| Q1 2026 | 103 | 56M | 25.1% | 26 / 33 | 18 / 19 | 19M | 23M |
| Q4 2025 | 98 | 69M | 30.6% | 28 / 30 | 20 / 18 | 37M | 3M |
| Q3 2025 | 91 | 35M | 15.4% | 20 / 14 | 32 / 17 | 7M | 5M |
| Q2 2025 | 89 | 32M | 14.2% | 20 / 25 | 23 / 38 | 5M | 22M |
| Q1 2025 | 107 | 49M | 21.7% | 31 / 22 | 32 / 10 | 11M | 6M |
| Q4 2024 | 88 | 44M | 19.6% | 22 / 29 | 19 / 28 | 10M | 22M |
| Q3 2024 | 95 | 58M | 25.7% | 17 / 37 | 18 / 17 | 7M | 3M |
| Q2 2024 | 96 | 57M | 25.5% | 18 / 37 | 28 / 12 | 5M | 4M |
| Q1 2024 | 90 | 57M | 25.3% | 24 / 27 | 26 / 7 | 13M | 3M |
| Q4 2023 | 74 | 47M | 20.9% | 10 / 28 | 24 / 12 | 2M | 6M |
| Q3 2023 | 76 | 51M | 22.6% | 11 / 32 | 13 / 14 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TNYA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,136,220 | 2.29% | $3.80M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,768,551 | 0.79% | $1.31M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,490,588 | 0.66% | $1.10M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 824,295 | 0.37% | $716.31K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 303,128 | 0.14% | $263.42K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 231,319 | 0.10% | $201.02K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 221,893 | 0.10% | $164.27K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 175,000 | 0.08% | $129.34K | 0.09% | Jun 30, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 161,857 | 0.07% | $119.63K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 120,429 | 0.05% | $104.65K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 113,232 | 0.05% | $83.69K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 83,260 | 0.04% | $61.54K | 0.00% | Jun 30, 2026 |
| T. Rowe Price Total Equity Market Index Fund | 31,453 | 0.01% | $23.25K | 0.00% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 24,395 | 0.01% | $18.06K | 0.00% | Jul 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 11,421 | 0.01% | $9.92K | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Faraz Ali | Chief Executive Officer, Director | 539,782 | 0.24% | Sep 11, 2026 |
| Whittemore Tingley | Chief Medical Officer | 263,073 | 0.12% | Sep 11, 2026 |
| Eric J. Hyllengren | Chief Financial Officer | – | – | Jul 14, 2026 |
| Tomohiro Higa | SVP, Finance | 118,267 | 0.05% | May 19, 2026 |
| Chihiro Saito | SVP, Accounting and Fin. Ops. | 60,983 | 0.03% | Nov 18, 2024 |
| Catherine Stehman-Breen | Director | 8,125 | 0.00% | May 29, 2026 |
| June Lee | Director | – | – | May 29, 2026 |
| Jeffrey T. Walsh | Director | – | – | May 29, 2026 |
| Deepak Srivastava | Director | 564,101 | 0.25% | May 29, 2026 |
| Amy L. Burroughs | Director | – | – | May 29, 2026 |
| Karah Herdman Parschauer | Director | – | – | May 29, 2026 |
| R. Sanders Williams | Director | 29,999 | 0.01% | May 29, 2026 |
| David V. Goeddel | Director, 10% owner | 49,313,559 | 21.99% | May 30, 2025 |
| Tim Kutzkey | 10% owner | – | – | Feb 26, 2026 |
| TCG Opportunity III GP, LLC | 10% owner | 0 | – | Feb 26, 2026 |
| Column Group Opportunity III, LP | 10% owner | – | – | Feb 26, 2026 |
| Peter Svennilson | 10% owner | – | – | Feb 26, 2026 |
| Column Group Iii Gp, Lp | 10% owner | 14,855,844 | 6.63% | Feb 26, 2026 |
| Column Group Iii-A, Lp | 10% owner | 1,958,509 | 0.87% | Feb 26, 2026 |
| Column Group Iii, Lp | 10% owner | 49,313,559 | 21.99% | Feb 26, 2026 |
| Column Group Opportunity III GP, LP | 10% owner | – | – | Feb 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Faraz Ali Chief Executive Officer, Director | Sep 10, 2026 | Award | +122,000 | – | – | 539,782 |
| Whittemore Tingley Chief Medical Officer | Sep 10, 2026 | Award | +49,000 | – | – | 263,073 |
| Whittemore Tingley Chief Medical Officer | Aug 17, 2026 | Sale | −1,637 | $0.71 | $1.16K | 218,223 |
| Whittemore Tingley Chief Medical Officer | Aug 17, 2026 | Sale | −2,279 | $0.71 | $1.62K | 214,073 |
| Whittemore Tingley Chief Medical Officer | Aug 17, 2026 | Sale | −1,871 | $0.71 | $1.33K | 216,352 |
| Whittemore Tingley Chief Medical Officer | Aug 17, 2026 | Sale | −1,637 | $0.71 | $1.16K | 219,860 |
| Faraz Ali Chief Executive Officer, Director | Aug 17, 2026 | Sale | −3,969 | $0.71 | $2.82K | 430,208 |
| Faraz Ali Chief Executive Officer, Director | Aug 17, 2026 | Sale | −5,837 | $0.71 | $4.14K | 434,177 |
| Faraz Ali Chief Executive Officer, Director | Aug 17, 2026 | Sale | −7,406 | $0.71 | $5.26K | 417,782 |
| Faraz Ali Chief Executive Officer, Director | Aug 17, 2026 | Sale | −5,020 | $0.71 | $3.56K | 425,188 |
| Tomohiro Higa SVP, Finance | May 18, 2026 | Sale | −1,485 | $0.79 | $1.17K | 118,267 |
| Faraz Ali Chief Executive Officer, Director | May 18, 2026 | Sale | −3,390 | $0.79 | $2.68K | 440,014 |
| Whittemore Tingley Chief Medical Officer | May 18, 2026 | Sale | −3,121 | $0.79 | $2.47K | 215,497 |
| TCG Opportunity III GP, LLC 10% owner | Feb 25, 2026 | Sale | −1,862,545 | $0.56 | $1.04M | 0 |
| TCG Opportunity III GP, LLC 10% owner | Feb 25, 2026 | Sale | −1,649,281 | $0.56 | $923.60K | 0 |
| TCG Opportunity III GP, LLC 10% owner | Feb 24, 2026 | Sale | −309,228 | $0.62 | $191.72K | 1,649,281 |
| TCG Opportunity III GP, LLC 10% owner | Feb 24, 2026 | Sale | −349,212 | $0.62 | $216.51K | 1,862,545 |
| Column Group Iii-A, Lp 10% owner | Feb 23, 2026 | Sale | −143,709 | $0.60 | $86.23K | 1,958,509 |
| Column Group Iii-A, Lp 10% owner | Feb 23, 2026 | Sale | −162,291 | $0.60 | $97.37K | 2,211,757 |
| Column Group Iii-A, Lp 10% owner | Feb 20, 2026 | Sale | −245,965 | $0.61 | $150.04K | 2,102,218 |
| Column Group Iii-A, Lp 10% owner | Feb 20, 2026 | Sale | −277,769 | $0.61 | $169.44K | 2,374,048 |
| Whittemore Tingley Chief Medical Officer | Feb 17, 2026 | Sale | −1,642 | $0.64 | $1.05K | 222,136 |
| Whittemore Tingley Chief Medical Officer | Feb 17, 2026 | Sale | −1,876 | $0.64 | $1.20K | 218,618 |
| Whittemore Tingley Chief Medical Officer | Feb 17, 2026 | Sale | −1,642 | $0.64 | $1.05K | 220,494 |
| Faraz Ali Chief Executive Officer, Director | Feb 17, 2026 | Sale | −3,979 | $0.64 | $2.55K | 448,436 |
| Faraz Ali Chief Executive Officer, Director | Feb 17, 2026 | Sale | −5,851 | $0.64 | $3.74K | 452,415 |
| Faraz Ali Chief Executive Officer, Director | Feb 17, 2026 | Sale | −5,032 | $0.64 | $3.22K | 443,404 |
| Tomohiro Higa SVP, Finance | Feb 17, 2026 | Sale | −611 | $0.64 | $391 | 122,610 |
| Tomohiro Higa SVP, Finance | Feb 17, 2026 | Sale | −2,022 | $0.64 | $1.29K | 119,752 |
| Tomohiro Higa SVP, Finance | Feb 17, 2026 | Sale | −836 | $0.64 | $535 | 121,774 |
| Column Group Iii-A, Lp 10% owner | Feb 11, 2026 | Sale | −1,905,115 | $0.68 | $1.30M | 2,348,183 |
| Column Group Iii-A, Lp 10% owner | Feb 11, 2026 | Sale | −2,151,458 | $0.68 | $1.46M | 2,651,817 |
| Column Group Iii-A, Lp 10% owner | Feb 10, 2026 | Sale | −182,295 | $0.82 | $149.48K | 4,803,275 |
| Column Group Iii-A, Lp 10% owner | Feb 10, 2026 | Sale | −161,422 | $0.82 | $132.37K | 4,253,298 |
| Faraz Ali Chief Executive Officer, Director | Feb 3, 2026 | Award | +158,600 | – | – | 458,266 |
| Tomohiro Higa SVP, Finance | Feb 3, 2026 | Award | +29,250 | – | – | 123,221 |
| Whittemore Tingley Chief Medical Officer | Feb 3, 2026 | Award | +48,750 | – | – | 223,778 |
| Whittemore Tingley Chief Medical Officer | Nov 17, 2025 | Sale | −2,877 | $1.33 | $3.83K | 169,926 |
| Faraz Ali Chief Executive Officer, Director | Nov 17, 2025 | Sale | −3,126 | $1.33 | $4.16K | 299,666 |
| Tomohiro Higa SVP, Finance | Nov 17, 2025 | Sale | −1,367 | $1.33 | $1.82K | 93,971 |
| Faraz Ali Chief Executive Officer, Director | Aug 18, 2025 | Sale | −4,920 | $1.25 | $6.15K | 302,792 |
| Faraz Ali Chief Executive Officer, Director | Aug 18, 2025 | Sale | −3,893 | $1.25 | $4.87K | 307,712 |
| Faraz Ali Chief Executive Officer, Director | Aug 18, 2025 | Sale | −5,720 | $1.25 | $7.15K | 311,605 |
| Whittemore Tingley Chief Medical Officer | Aug 18, 2025 | Sale | −1,837 | $1.25 | $2.30K | 172,803 |
| Whittemore Tingley Chief Medical Officer | Aug 18, 2025 | Sale | −1,608 | $1.25 | $2.01K | 174,640 |
| Whittemore Tingley Chief Medical Officer | Aug 18, 2025 | Sale | −1,608 | $1.25 | $2.01K | 176,248 |
| Tomohiro Higa SVP, Finance | Aug 18, 2025 | Sale | −523 | $1.25 | $654 | 97,777 |
| Tomohiro Higa SVP, Finance | Aug 18, 2025 | Sale | −717 | $1.25 | $896 | 97,060 |
| Tomohiro Higa SVP, Finance | Aug 18, 2025 | Sale | −1,722 | $1.25 | $2.15K | 95,338 |
| Whittemore Tingley Chief Medical Officer | May 16, 2025 | Sale | −2,937 | $0.44 | $1.29K | 171,856 |
| Tomohiro Higa SVP, Finance | May 16, 2025 | Sale | −1,390 | $0.44 | $612 | 98,300 |
| Faraz Ali Chief Executive Officer, Director | May 16, 2025 | Sale | −3,189 | $0.44 | $1.40K | 317,325 |
| Faraz Ali Chief Executive Officer, Director | Mar 10, 2025 | Sale | −5,794 | $0.54 | $3.13K | 324,461 |
| Faraz Ali Chief Executive Officer, Director | Mar 10, 2025 | Sale | −3,947 | $0.54 | $2.13K | 320,514 |
| Whittemore Tingley Chief Medical Officer | Mar 10, 2025 | Sale | −4,073 | $0.54 | $2.20K | 176,391 |
| Whittemore Tingley Chief Medical Officer | Mar 10, 2025 | Sale | −1,727 | $0.54 | $933 | 180,464 |
| Whittemore Tingley Chief Medical Officer | Mar 10, 2025 | Sale | −1,598 | $0.54 | $863 | 174,793 |
| Tomohiro Higa SVP, Finance | Mar 10, 2025 | Sale | −620 | $0.54 | $335 | 100,535 |
| Tomohiro Higa SVP, Finance | Mar 10, 2025 | Sale | −845 | $0.54 | $456 | 99,690 |
| Tomohiro Higa SVP, Finance | Mar 10, 2025 | Sale | −1,017 | $0.54 | $549 | 101,155 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ali Faraz Officer, Director | Aug 17, 2026 | 22,232 | $15.78K | Aug 17, 2026 | Restricted Stock Unit |
| Tingley Whittemore Officer | Aug 17, 2026 | 7,424 | $5.27K | Aug 17, 2026 | Restricted Stock Unit |
| Column Group Iii, Lp 10% Stockholder | Feb 25, 2026 | 939,273 | $565.44K | Feb 25, 2026 | Series A financing |
| Column Group Iii-A, Lp 10% Stockholder | Feb 25, 2026 | 1,060,727 | $596.55K | Feb 25, 2026 | Series B financing |
| Column Group Iii, Lp 10% Stockholder | Feb 20, 2026 | 1,408,910 | $872.54K | Feb 20, 2026 | Series A financing |
| Column Group Iii-A, Lp 10% Stockholder | Feb 20, 2026 | 1,591,090 | $985.36K | Feb 20, 2026 | Series A financing |
| Tingley Whittemore Officer | Feb 17, 2026 | 5,160 | $3.32K | Feb 17, 2026 | Restricted Stock Unit |
| Ali Faraz Officer, Director | Feb 17, 2026 | 14,862 | $9.56K | Feb 17, 2026 | Restricted Stock Unit |
| Column Group Iii-A, Lp 10% Stockholder | Feb 11, 2026 | 742,663 | $504.79K | Feb 11, 2026 | Series A financing |
| Column Group Iii, Lp 10% Stockholder | Feb 11, 2026 | 657,627 | $446.99K | Feb 11, 2026 | Series A financing |
| Column Group Iii, Lp 10% Stockholder | Feb 10, 2026 | 1,408,910 | $1.11M | Feb 10, 2026 | Series A financing |
| Column Group Iii-A, Lp 10% Stockholder | Feb 10, 2026 | 1,591,090 | $1.26M | Feb 10, 2026 | Series A financing |
| Tingley Whittemore Officer | Aug 18, 2025 | 5,053 | $6.33K | Aug 18, 2025 | Restricted Stock Unit |
| Ali Faraz Officer, Director | Aug 18, 2025 | 14,533 | $18.21K | Aug 18, 2025 | Restricted Stock Unit |
| Ali Faraz Officer, Director | Mar 10, 2025 | 9,741 | $5.24K | Mar 10, 2025 | Restricted Stock Unit |